<DOC>
	<DOCNO>NCT01734928</DOCNO>
	<brief_summary>The purpose study compare efficacy combination Pomalidomide , Bortezomib Dexamethasone combination Bortezomib Dexamethasone patient relapsed/refractory multiple myeloma . This study also assess safe combination Pomalidomide , Bortezomib Dexamethasone compare combination Bortezomib Dexamethasone</brief_summary>
	<brief_title>Safety Efficacy Pomalidomide , Bortezomib Low-dose Dexamethasone Subjects With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Must â‰¥ 18yrs time signing informed consent . Must document diagnosis multiple myeloma measureable disease serum urine protein electrophoresis . Must least 1 great 3 prior antimyeloma regimen . Must document disease progression last antimyeloma therapy . All subject must receive prior treatment lenalidomide contain regimen least 2 consecutive cycle . Refractory prior Bortezomibcontaining therapy 1.3 mg/m2 dose twice weekly dose schedule . Peripheral neuropathy Grade 3 , Grade 4 Grade 2 pain within 14 day prior randomization . Nonsecretory multiple myeloma . Subjects severe renal impairment require dialysis . Previous therapy pomalidomide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Pomalidomide</keyword>
</DOC>